These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date and reported results 2004-000356-17 Phase IIIB, international, single group, open study to define an optimal monitor-ing of IGF-I in children treated with NutropinAq™, using a novel capillary blood collection method 2008-10-22 bad-data
Completed, but no date 2004-001091-40 A Phase III, Prospective, Multicentre, Randomised, Open, Parallel Group Comparison of Lanreotide Autogel (90 and 120mg) Administered by Deep Subcutaneous Injection Every Four Weeks, with Sandostatin L... bad-data
Reported results 2004-001164-41 AN EXPLORATORY, OPEN, TWO-ARM, MATCH-CONTROL, RANDOMISED AND STRATIFIED PILOT PHASE II STUDY ASSESSING THE PREVENTION OF THE ADVERSE EFFECTS OF LONG-TERM HIGH-DOSE GLUCOCORTICOID THERAPY BY GROWTH HOR... 2006-07-24 due-trials
Ongoing, reported early 2004-001443-29 A multicentre, randomized, double-blind, parallel and controlled with placebo pilot study to evaluate the efficacy and safety of a single dose of botulinum toxin Type A (Dysport®) associated with reha... not-yet-due
Reported results 2004-001845-13 A phase II, multicentre, multinational, prospective, randomised, double-blind, placebo controlled study assessing the efficacy and safety of a single application of three doses of Dysport in patients ... 2006-05-18 due-trials
Reported results 2004-002086-20 Open, multicentre study on the equivalent efficacy and safety of Botulinum toxin A (500 Units Dysport®) in the treatment of heterogeneous forms of cervical dystonia 2008-04-30 due-trials
Reported results 2004-002871-18 Phase II, open, single group,multicentre study to evaluate the efficacy and safety of Somatuline Autogel® (120 mg) administered every 4 weeks by deep subcutaneous injection in the tumour´s growth stab... 2009-11-02 due-trials
Ongoing, reported early 2004-003937-14 A phase II, unicentre, randomized, double-blind, parallel and placebo-controlled, pilot study to evaluate the efficacy and safety of Somatuline Autogel (60 mg) in patients with active thyroid-associat... not-yet-due
Ongoing, reported early 2005-000709-70 A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia not-yet-due
Completed, but no date, and reported results 2005-001794-10 A Phase IV, Randomised, Double-blind, Dose-ranging, Study in Children and Young People to determine the Optimal Dose of Botulinum Toxin Type-A (Dysport®) in Managing the Symptoms of Hip Muscle Spastic... bad-data
Reported results 2005-002349-38 Phase III multicentre, Randomised, Double Blind, Comparative study to assess the efficacy and safety of lanreotide 30mg versus placebo as a palliative treatment of clinical symptoms associated with in... 2008-10-01 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-004904-35 Estudio multicéntrico fase III, aleatorizado, doble ciego, estratificado y comparativo, controlado con placebo y de grupos paralelos, para evaluar el efecto de lanreotida Autogel 120 mg, administrado ... 2013-06-13 bad-data
Completed, but no date 2005-005058-31 PHASE II MULTI-CENTRIC, RANDOMISED, OPEN-LABEL, PARALLEL-GROUP STUDY TO ASSESS THE NON-INFERIORITY OF PAMORELIN® 11,25MG SC INJECTED VERSUS PAMORELIN® 11,25MG IM INJECTED IN PATIENTS SUFFERING FROM AD... bad-data
Ongoing 2005-005060-92 Phase IIIB, Double Blind, Placebo Controlled, International, Multicenter, Parallel Group Study, to Assess the Efficacy and Safety of Testim Gel in Combination with a Phosphodiesterase V Inhibitor (Tad... not-yet-due
Ongoing, reported early 2005-005644-11 Phase III, multicentre, non comparative, open and single stage study to assess the efficacy and safety of pamoate of triptorelin 11.25 mg in children with precocious puberty not-yet-due
Listed as ongoing, but also has a completion date and reported results 2006-000297-72 Phase III, multicentre, open study to assess the efficacy and safety profiles of the co-administration of lanreotide Autogel 120 mg (administered via deep subcutaneous injections every 28 days) and pe... 2009-10-13 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-001511-30 A phase III, single arm, multicentre study to evaluate the efficacy and safety of a subcutaneous four-month sustained-release formulation of triptorelin, a gonadotrophin releasing hormone analogue in ... 2007-10-11 bad-data
Completed, but no date 2006-005200-13 Phase II multi-centre, randomised, open, comparative study of the safety and efficacy of transdermal testosterone (Testim®) compared to intramuscular testosterone depot for the induction of puberty in... bad-data
Not reported 2006-007055-41 A phase II, open-label, multicentre study to evaluate the pharmacodynamic profile, the efficacy and the safety of a 6-month sustained-release formulation of triptorelin in patients with prostate cance... 2007-06-08 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-000155-34 PHASE IIIb, MULTICENTRE, OPEN-LABEL, SINGLE-ARM, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 mg ADMINISTERED EVERY 28 DAYS AS PRIMARY MEDICAL TREATMENT IN ACROMEGALIC PATIENTS WI... 2012-02-13 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-002999-34 A PHASE II, INTERNATIONAL, MULTI-CENTRE, PROSPECTIVE, RANDOMISED, PARALLEL-GROUP, DOUBLE-BLIND, DOSE-RANGING, PLACEBO-CONTROLLED, 12-WEEK, PRINCEPS STUDY TO ASSESS THE EFFICACY AND SAFETY OF A ONE INJ... 2009-12-15 bad-data
Ongoing, reported early 2007-005371-34 EFFICACY OF EGb 761® 120 mg bid VERSUS PLACEBO IN PATIENTS SUFFERING FROM FRIEDREICH ATAXIA A 3 months, phase II, randomised, double blind, placebo-controlled, parallel groups, clinical study. not-yet-due
Ongoing, reported early 2007-005377-63 Effect of oral EGb 761® on Brain Glucose Metabolism in Three Groups of Elderly with Memory Complaint, mild Alzheimer's Disease, and Cognitively Normal Elderly. Phase II, randomised, double-blind, par... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2007-005838-37 A PROSPECTIVE, INTERNATIONAL, MULTI-CENTRIC, OPEN-LABEL STUDY TO ASSESS THE EFFICACY OF AN EXTENDED INJECTION INTERVAL SCHEDULE OF LANREOTIDE AUTOGEL 120 MG IN ACROMEGALIC SUBJECTS WHO ARE BIOCHEMICAL... 2013-05-20 bad-data
Reported results 2007-005958-23 A Phase II, Randomised, Double-Blind Study to Compare the Safety and Efficacy of One Treatment Cycle of Clostridium Botulinum Type A Toxin (50 Units) When Reconstituted from Either a 125 Unit or a 500... 2008-08-14 due-trials
Reported results 2007-006514-42 A PHASE IV, OPEN-LABEL, RANDOMISED, CROSS-OVER STUDY TO ASSESS PATIENT PREFERENCE AND HEALTH ECONOMY IN PATIENTS WITH NEUROENDOCRINE TUMOURS, TREATED WITH LANREOTIDE AUTOGEL GIVEN AS SELF ADMINISTRATI... 2010-10-20 due-trials
Reported results 2008-000500-83 A phase II exploratory, ascending dose, multicentre study to investigate the pharmacodynamics, pharmacokinetics, safety and tolerability, of BIM23A760 in acromegalic patients. 2009-02-24 due-trials
Completed, but no date, and reported results 2008-000565-39 FOLLOW-UP OF THE PHASE III, MULTICENTRE, NON COMPARATIVE, ONE SINGLE GROUP, OPEN STUDY TO ASSESS THE LONG-TERM EFFICACY AND TOLERABILITY OF PAMOATE OF TRIPTORELIN 11.25 MG IN CHILDREN WITH PRECOCIOUS ... bad-data
Listed as ongoing, but also has a completion date and reported results 2008-004019-36 Estudio abierto, de extensión, con lanreotida autogel 120 mg en pacientes con tumor endocrino entero-pancreático no funcional. 2015-12-04 bad-data
Reported results 2009-009356-20 A PHASE II/III, MULTI-CENTRE, PROSPECTIVE, EXPLORATORY, OPEN LABEL STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 MG IN THE SYMPTOMATIC TREATMENT OF PATIENTS WITH REFRACTORY DIARRHE... 2012-08-09 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-010613-68 A phase II international multicentre randomised open label study of oral steroid sulphatase inhibitor BN83495 versus megestrol acetate (MA) in women with advanced or recurrent endometrial cancer 2013-07-10 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-010787-42 PHASE II, OPEN, RANDOMISED, PARALLEL GROUP, NONCOMPARATIVE MULTICENTRE STUDY TO ASSESS THE EFFICACY AND SAFETY OF REPEATED SUBCUTANEOUS (S.C.) ADMINISTRATION OF DIFFERENT DOSES OF BIM 23A760 IN ACROME... 2011-01-31 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-012786-58 Prostate cancer anticen-3 (PCA-3) and TMPRSS2-ERG (T2-ERG) score changes during initiation of androgen deprivation theray (ADT) with triptorelin 22.5 mg in patients with advanced prostate cancer (PCA)... 2013-02-28 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-013222-16 ESTUDIO EN FASE II ABIERTO, ADAPTATIVO, MULTICÉNTRICO, CON AUMENTO Y AJUSTE DE LA DOSIS PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE LA ADMINISTRACIÓN SUBCUTÁNEA REPETIDA DE DISTINTAS DOSIS DE BIM 23A76... 2011-01-31 bad-data
Reported results 2009-015868-34 A PHASE III, MULTICENTRE, DOUBLE BLIND, PROSPECTIVE, RANDOMISED, PLACEBO CONTROLLED STUDY, ASSESSING THE EFFICACY AND SAFETY OF DYSPORT USED FOR THE TREATMENT OF LOWER LIMB SPASTICITY IN ADULT SUBJECT... 2014-05-13 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-017709-12 A PHASE III, MULTICENTRE, DOUBLE BLIND, PROSPECTIVE, RANDOMISED, PLACEBO CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF DYSPORT USED IN THE TREATMENT OF LOWER LIMB SPASTICITY IN CHILDREN WITH D... 2014-06-25 bad-data
Reported results 2009-017723-26 A phase III, prospective, multicentre, open label, extension study, to assess the long term safety and efficacy of repeated treatment of Dysport® intramuscular injection in the treatment of lower lim... 2015-04-14 due-trials
Reported results 2010-019066-92 A double-blind, randomized placebo-controlled clinical trial investigating the efficacy and safety of Somatuline Depot (lanreotide) Injection in the treatment of carcinoid syndrome 2015-12-15 due-trials
Reported results 2010-019069-28 A phase III, multicentre, prospective, double blind, randomised, placebo controlled study, assessing the efficacy and safety of Dysport intramuscular injections used for the treatment of upper limb sp... 2013-09-04 due-trials
Reported results 2010-019085-82 A PHASE II, DOUBLE BLIND, RANDOMISED, PLACEBO AND ACTIVE COMPARATOR CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF THREE DOSES OF DYSPORT RU (20 U, 50 U AND 75 U) ADMINISTERED AS A SINGLE TREAT... 2011-09-27 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-019102-17 A PHASE III, PROSPECTIVE, MULTICENTRE, OPEN LABEL, EXTENSION STUDY ASSESSING THE LONG TERM SAFETY AND EFFICACY OF REPEATED TREATMENT WITH DYSPORT USED IN THE TREATMENT OF LOWER LIMB SPASTICITY IN CHIL... 2015-01-14 bad-data
Completed, but no date 2010-019158-41 ENSAYO CLÍNICO DE PRUEBA DE CONCEPTO, MULTICÉNTRICO, PROSPECTIVO, ALEATORIZADO, ABIERTO Y PARALELO, PARA VALORAR LA EFICACIA DE LA BRAQUITERAPIA CON O SIN TRATAMIENTO HORMONAL CON TRIPTORELINA 22,5MG ... bad-data
Reported results 2010-019162-83 A phase III, multicentre, prospective, open label extension study to assess the long term safety and efficacy of repeated treatment of Dysport intramuscular injections used for the treatment of upper ... 2014-12-09 due-trials
Reported results 2010-019632-12 A phase II, multicentre, open, prospective, randomised, parallel-group, pharmacodynamic equivalence study on intramuscular versus subcutaneous applications of Triptorelin pamoate (Pamorelin® LA 11.25 ... 2012-05-07 due-trials
Completed, but no date, and reported results 2010-019862-10 Randomised, phase III multicenter, open study of lanreotide in non metastatic castration-resistant prostate cancer patients presenting elevated Chromogranin A levels bad-data
Reported results 2010-019907-43 A phase III, randomised, double blind and open label phase, active and placebo controlled study comparing the short term efficacy of two formulations of clostridium botulinum type A toxin (Dysport and... 2013-06-04 due-trials
Completed, but no date 2010-019980-13 Predictive value of baseline and stimulated serum IGF-I and IGFBP-3 during a dose-escalation IGF-I generation test with NutropinAq for the 1 year growth response to growth hormone (GH) therapy in shor... bad-data
Not reported 2010-020742-10 Recombinant Human Insulin-like Growth Factor (rhIGF-1) and Growth Hormone (rhGH) Combination Therapy of Pre-Pubertal Children with Idiopathic Growth Hormone Deficiency and Poor Response to First Year ... 2011-06-30 due-trials
Ongoing 2010-021817-22 A PHASE III, MULTICENTRE, DOUBLE BLIND, PROSPECTIVE, RANDOMISED, CONTROLLED, MULTIPLE TREATMENT STUDY ASSESSING EFFICACY AND SAFETY OF DYSPORT USED IN THE TREATMENT OF UPPER LIMB SPASTICITY IN CHILDRE... not-yet-due
Reported results 2010-023210-31 A PHASE IIA, MULTICENTRE, DOUBLE BLIND, SINGLE DOSE, PARALLEL GROUP, PLACEBO CONTROLLED, CLINICAL PILOT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SINGLE DOSE, INTRA-DETRUSOR INJECTIONS OF 750 UNITS O... 2013-03-21 due-trials
Reported results 2011-001935-21 An interventional non-therapeutic study to assess ex vivo basophil activation in response to various preparations of taspoglutide and related items in blood samples from subjects who previously receiv... 2011-12-21 due-trials
Ongoing, reported early 2011-004213-16 A PHASE IV, RANDOMISED, OPEN-LABEL, MULTI-CENTRE STUDY TO ASSESS THE IMPACT ON DISEASE CONTROL, SAFETY, PATIENT AND CLINICIAN EXPERIENCE OF CHANGING PATIENTS WITH ADVANCED PROSTATE CANCER FROM A 3-MON... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2011-005375-16 A PHASE III PROSPECTIVE, MULTI-CENTER, RANDOMISED, EVALUATOR-BLINDED STUDY TO COMPARE NEUROMUSCULAR JUNCTION (NMJ) TARGETED TECHNIQUE FOR DYSPORT INJECTIONS IN UPPER LIMB SPASTICITY POST STROKE OR TRA... 2013-10-31 bad-data
Reported results 2012-001038-32 A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PROOF OF CONCEPT STUDY OF MAINTENANCE THERAPY WITH TASQUINIMOD IN PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER WHO ARE NOT PROGRESSING AF... 2015-05-27 due-trials
Reported results 2012-001279-35 A phase III single arm study to evaluate the efficacy, safety and local tolerability of a subcutaneous 3‑month formulation of triptorelin pamoate (11.25 mg) in patients with locally advanced or metast... 2013-10-09 due-trials
Ongoing, reported early 2012-002326-75 A multicentre, open label, early stopping design, proof of concept study with tasquinimod in treating patients with advanced or metastatic hepatocellular, ovarian, renal cell and gastric carcinomas. not-yet-due
Not reported 2013-001697-17 PHASE II, MULTICENTRE, OPEN LABEL STUDY TO EVALUATE THE EFFICACY OF THE COMBINATION OF LANREOTIDE AUTOGEL 120 MG AND TEMOZOLOMIDE IN PATIENTS WITH PROGRESSIVE GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE T... 2017-06-01 due-trials
Ongoing 2013-002174-43 AN INTERNATIONAL, MULTICENTRIC, PROSPECTIVE, OPEN LABEL STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 MG ASSOCIATED TO STANDARD OF CARE IN THE TREATMENT OF CLINICAL SYMPTOMS ASSOC... not-yet-due
Ongoing 2013-002194-22 A Phase IV, Multicentre, Open label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progress... not-yet-due
Reported results 2013-002321-34 A phase III, double blind, randomised, placebo controlled study to assess the efficacy and safety of a single treatment of Clostridium botulinum toxin type A to improve the appearance of moderate to s... 2015-08-31 due-trials
Reported results 2013-002899-41 A dose escalation, proof of concept, phase IIa study to investigate the safety and tolerability, the pharmacokinetic and the 2016-03-31 due-trials
Ongoing 2013-003176-12 A PHASE II, MULTICENTRE, RANDOMIZED CONTROLLED STUDY EVALUATING THE QUALITY OF LIFE IN PATIENTS WITH INOPERABLE MALIGNANT BOWEL OBSTRUCTION TREATED WITH LANREOTIDE AUTOGEL 120 MG IN COMBINATION WITH S... not-yet-due
Listed as ongoing, but also has a completion date 2014-002389-62 Phase IIA, open label, dose ascending study to determine the maximum tolerated dose, safety and tolerability, pharmacokinetics and parmacodynamics of a single dose of lanreotide PRF in subjects with a... 2017-11-28 bad-data
Listed as ongoing, but also has a completion date 2014-003841-86 A phase III, randomised, double blind, placebo controlled and open label phase, multicentre study to investigate the efficacy and safety of BTX-A-HAC NG in the treatment of moderate to severe glabella... 2016-12-02 bad-data
Ongoing 2014-005607-24 Efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours having pro... not-yet-due
Ongoing 2015-000507-44 A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT® F... not-yet-due
Listed as ongoing, but also has a completion date 2015-000554-38 A Phase III, Multicenter, Double Blind, Randomised, Placebo Controlled Study to Assess the Efficacy and the Safety of a Single Cycle of Dysport Solution in the Treatment of Upper Limb Spasticity in Ad... 2017-06-16 bad-data
Ongoing 2015-001138-10 Efficacy of diosmectite (Smecta®) in the symptomatic treatment of acute diarrhoea in adults. A multicentre, randomised, double-blind, placebo-controlled, parallel groups study not-yet-due
Ongoing 2015-002867-41 An international multi-center, open-label study to evaluate safety, tolerability, biodistribution, dosimetry and preliminary efficacy of 177Lu-OPS201 for the therapy of somatostatin receptor-positive ... not-yet-due
Ongoing 2015-003471-30 A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT® F... not-yet-due
Not reported 2015-003868-37 A phase IIa, open-label, single-arm, two stage, multi-centre study to investigate the pharmacodynamics, pharmacokinetics, safety and tolerability of repeated subcutaneous administration of BIM23B065 i... 2017-06-02 due-trials
Ongoing 2015-004992-62 A PHASE 3, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, STUDY OF THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL/ DEPOT 120 MG PLUS BSC VS. PLACEBO PLUS BSC FOR TUMOR CONTROL IN SUBJECTS WITH WE... not-yet-due
Ongoing 2016-001989-29 An International, Multicentre, Prospective, Single Arm Study to Assess the Effect on Voluntary Movements of AbobotulinumtoxinA 1500 U Administered in Both Upper and Lower Limbs in Conjunction with a G... not-yet-due
Other 2016-002265-60 Efficacy, safety and tolerability of a bowel cleansing preparation (Eziclen/Izinova®) in paediatric subjects undergoing colonoscopy: a Phase III, multicentre, randomised, comparative study versus Klea... not-yet-due
Ongoing 2016-004928-39 A multicentre, randomised, dose-confirmation, factorial phase II study to evaluate the optimal dose of 68Ga-OPS202 as a PET imaging agent in subjects with gastroenteropancreatic neuroendocrine tumour ... not-yet-due
Ongoing 2017-004261-26 RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection not-yet-due